Aztreonam

C difficile risk
Medium
Oral Bioavailability
N/A

Dosing

2 g IV q6 - 8h

0 - 10 eGFR10 - 50 eGFR50+ eGFR2 g IV q24h3 - 4g IV daily divided q8 - 12h2 g IV q8h

General Information

  • Therapy of gram negative infections including Pseudomonas, particularly in patients with penicillin and cephalosporin allergy or when there is no alternative susceptible agent

  • Nebulized form used in cystic fibrosis patients

  • Empiric therapy for febrile neutropenia

Breastfeeding: Limited information indicates that aztreonam produces low levels in milk that are not expected to cause adverse effects in breastfed infants.

Monitor liver enzymes

  • Elevated liver enzymes

  • Cytopenias

  • Eosinophilia

  • Phlebitis at injection site

  • Rash/allergy

  • CNS toxicity

Antimicrobial class: Monobactam